Log in

NASDAQ:CLRBCellectar Biosciences Stock Price, Forecast & News

$1.41
+0.07 (+5.22 %)
(As of 07/3/2020 01:32 PM ET)
Add
Compare
Today's Range
$1.38
Now: $1.41
$1.48
50-Day Range
$1.03
MA: $1.31
$1.51
52-Week Range
$1.01
Now: $1.41
$3.33
Volume1.09 million shs
Average Volume1.14 million shs
Market Capitalization$13.25 million
P/E RatioN/A
Dividend YieldN/A
Beta1.69
Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refractory (R/R) multiple myeloma (MM) and a range of B-cell malignancies, as well as in Phase I clinical study for R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is targeted to treat solid tumors. It has collaborative PDC programs with Pierre Fabre to develop CLR 1800 Series; Avicenna Oncology GMBH to develop CLR 2000 Series; Onconova Therapeutics, Inc. to develop CLR 2100 and 2200 Series; and Orano Med to develop novel PDCs. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.
Read More
Cellectar Biosciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.97 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CLRB
CUSIPN/A
Phone608-441-8120

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.84 per share

Profitability

Net Income$-14,090,000.00

Miscellaneous

Employees7
Market Cap$13.25 million
Next Earnings Date8/10/2020 (Estimated)
OptionableNot Optionable

Receive CLRB News and Ratings via Email

Sign-up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter.

Cellectar Biosciences (NASDAQ:CLRB) Frequently Asked Questions

How has Cellectar Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Cellectar Biosciences' stock was trading at $1.80 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CLRB stock has decreased by 21.7% and is now trading at $1.41. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Cellectar Biosciences?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectar Biosciences in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cellectar Biosciences.

When is Cellectar Biosciences' next earnings date?

Cellectar Biosciences is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Cellectar Biosciences.

How were Cellectar Biosciences' earnings last quarter?

Cellectar Biosciences Inc (NASDAQ:CLRB) released its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.35) by $0.07. View Cellectar Biosciences' earnings history.

When did Cellectar Biosciences' stock split? How did Cellectar Biosciences' stock split work?

Cellectar Biosciences's stock reverse split before market open on Tuesday, July 17th 2018. The 1-10 reverse split was announced on Friday, July 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 13th 2018. An investor that had 100 shares of Cellectar Biosciences stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for CLRB?

5 brokers have issued 1-year target prices for Cellectar Biosciences' shares. Their forecasts range from $3.00 to $10.00. On average, they anticipate Cellectar Biosciences' stock price to reach $5.40 in the next year. This suggests a possible upside of 283.0% from the stock's current price. View analysts' price targets for Cellectar Biosciences.

Has Cellectar Biosciences been receiving favorable news coverage?

News coverage about CLRB stock has been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cellectar Biosciences earned a media sentiment score of 1.6 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news about Cellectar Biosciences.

Who are some of Cellectar Biosciences' key competitors?

What other stocks do shareholders of Cellectar Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectar Biosciences investors own include Hudbay Minerals (HBM), Zynga (ZNGA), Quantum (QTM), Baytex Energy (BTE), Sherritt International (S), Bombardier (BDRBF), Encana (ECA), Bombardier, Inc. Class B (BBD.B), Bonavista Energy (BNP) and Hudbay Minerals (HBM).

Who are Cellectar Biosciences' key executives?

Cellectar Biosciences' management team includes the following people:
  • Mr. James V. Caruso, Pres, CEO & Director (Age 60)
  • Mr. Jarrod Longcor, Chief Bus. Officer (Age 46)
  • Mr. Charles T. Bernhardt, Interim Chief Financial Officer (Age 58)
  • Gregory J. Lynch, Sec.

What is Cellectar Biosciences' stock symbol?

Cellectar Biosciences trades on the NASDAQ under the ticker symbol "CLRB."

How do I buy shares of Cellectar Biosciences?

Shares of CLRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cellectar Biosciences' stock price today?

One share of CLRB stock can currently be purchased for approximately $1.41.

How big of a company is Cellectar Biosciences?

Cellectar Biosciences has a market capitalization of $13.25 million. The biopharmaceutical company earns $-14,090,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. Cellectar Biosciences employs 7 workers across the globe.

What is Cellectar Biosciences' official website?

The official website for Cellectar Biosciences is www.cellectar.com.

How can I contact Cellectar Biosciences?

Cellectar Biosciences' mailing address is 100 CAMPUS DRIVE, FLORHAM PARK NJ, 07932. The biopharmaceutical company can be reached via phone at 608-441-8120 or via email at [email protected]

This page was last updated on 7/3/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.